Denali therapeutics announces upcoming presentations on eif2b activator dnl343 and ripk1 inhibitor sar443820/dnl788 at the 2021 annual northeast amyotrophic lateral sclerosis (neals) meeting

South san francisco, calif., sept. 29, 2021 (globe newswire) -- denali therapeutics inc. (nasdaq: dnli), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (bbb) for neurodegenerative diseases, today announced upcoming presentations at the 2021 annual northeast amyotrophic lateral sclerosis (neals) meeting being held virtually, october 6-7.
DNLI Ratings Summary
DNLI Quant Ranking